Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Eli Lilly (NY: LLY )

790.21 -17.58 (-2.18%)
Official Closing Price Updated: 7:00 PM EDT, Jul 30, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 3,846,210
Open 815.18
Bid (Size) 786.51 (19)
Ask (Size) 791.50 (1)
Prev. Close 807.79
Today's Range 775.81 - 821.90
52wk Range 446.89 - 966.10
Shares Outstanding N/A
Dividend Yield 0.57%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
What's Going On With Eli Lilly Today?
Eli Lilly & Co shares are trading lower Tuesday. Here's what you need to know. 
Via Benzinga
3 Biotech Stocks That Could Make Your Summer Unforgettable
If you want to do well with biotech stocks, trade the anticipation of news. Here are three stocks to consider. 
Via InvestorPlace

Performance

YTD
+33.44%
+33.44%
1 Month
-13.58%
-13.58%
3 Month
+7.19%
+7.19%
6 Month
+22.51%
+22.51%
1 Year
+73.84%
+73.84%

More News

Read More
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
This Is What Whales Are Betting On Eli Lilly and Co
Via Benzinga
Unlocking the Next 3 Trillion-Dollar Stock Opportunities
Via InvestorPlace
1 Weight Loss Pharma Stock to Buy, and 1 to Consider
Via The Motley Fool
Unpacking the Latest Options Trading Trends in Eli Lilly and Co
Via Benzinga
Is Eli Lilly Stock a Buy?
Via The Motley Fool
Analyzing Eli Lilly and Co In Comparison To Competitors In Pharmaceuticals Industry
Via Benzinga
Healthy Profits: 7 Healthcare Stocks to Build a Lifetime of Wealth
Via InvestorPlace
DexCom Stock Plunged Over 40% Last Week. Are Eli Lilly's and Novo Nordisk's Drugs to Blame?
Via The Motley Fool
Eli Lilly’s $123 Billion Market Value Drop: A Strategic Buying Opportunity?
Via Talk Markets
3 Overlooked Stocks Poised for a Breakout Very Soon
Via InvestorPlace
What Will Be the Best Weight Loss Drug Stock of 2030: Eli Lilly, or Novo Nordisk?
Via The Motley Fool
Weight Loss Drug Stocks Just Took a Hit. Should You Buy the Stock That Caused It?
Via The Motley Fool
Attention, Growth Investors: This Biotech Stock Is Crushing Nvidia.
Via The Motley Fool
7 Smart Stocks to Buy BEFORE They Report Q2 Earnings
Via InvestorPlace
Home Depot Stock Turned $1,000 Into $17.5 Million, and One of Its Founders Just Revealed His Investing Secrets to Achieve Generational Wealth
Via The Motley Fool
Week In Review: Nanjing Triastek Partners With BioNTech In A $1.2 Billion Drug Development Deal
Via Talk Markets
Novo Nordisk's Next-Gen Diabetes Candidate Could Challenge Ozempic -- Is the Stock a Buy?
Via The Motley Fool
These 2 Growth Stocks Are Set to Soar This Summer and Beyond
Via The Motley Fool
Bull Market Buys: 2 Growth Stocks to Own for the Long Run
Via The Motley Fool
SPDR ETF Report For Friday, July 26
Via Talk Markets
Topics ETFs
Stock Market Diverges, With Tesla, Google, ServiceNow, GE In Focus: Weekly Review
Via Investor's Business Daily
Biogen/Eisai's Alzheimer's Drug Leqembi Gets 'No Go' From European Drug Regulator's Advisory Panel, Cites Serious Side Events
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.